Skip to main content

Table 3 Baseline demographic and clinical characteristics of the patients who developed hypophosphatemia during the continuous veno-venous hemofiltration therapy period a

From: Hypophosphatemia during continuous veno-venous hemofiltration is associated with mortality in critically ill patients with acute kidney injury

Characteristics Patients
(N= 521)
Survivors
(n= 260)
Non-survivors
(n= 261)
P
Mean age (yr) 60.34 57.97 62.71 0.002
Male sex (%) 326 (62.6) 163 (62.7) 163 (62.5) >0.999
Premorbidity (%) 347 (66.6) 155 (59.6) 192 (73.6) 0.001
 Cardiovascular disease 122 56 66  
 Liver disease 66 24 42  
 Pulmonary disease 25 12 13  
 Cancer 51 21 30  
 Renal disease 43 25 18  
 Hematological disease 22 7 15  
Other 18 10 8  
Recent surgery (%) 209 (40.1) 104 (40.0) 105 (40.2) 0.929
Sepsis (%) 304 (58.3) 137 (52.7) 167 (64.0) 0.016
 Chest 177 (58.2) 68 (49.6) 109 (65.3)  
 Abdomen 92 (30.3) 51 (37.2) 41 (24.6)  
 Bloodstream, including line-related infection 25 (8.2) 13 (9.5) 12 (7.2)  
 Other or unknown source 10 (3.3) 5 (3.6) 5 (3.0)  
APACHE II score (mean) 20.86 19.32 22.44 <0.001
Length of mechanical ventilation (days) 9.56 9.68 9.44 0.700
Prescribed dose of CVVH (mean in first 72 hours, ml/kg/h) 50.78 50.12 51.43 0.272
Delivered dose of CVVH (median in first 72 hours, ml/kg/h) 42.23 41.78 42.68 0.235
Therapeutic time of CVVH (days) 9.49 9.60 9.37 0.710
Phosphate supplementation (%) 355 (68.1) 175 (67.3) 180 (69.0) 0.707
Ratio of CVVH therapy days with hypophosphatemia to total CVVH therapy days (mean) 0.58 0.50 0.65 <0.001
 High ratiob (%) 242 (46.4) 96 (36.9) 146 (55.9)  
 Low ratioc (%) 279 (53.6) 164 (63.1) 115 (44.1)  
  1. a Acute Physiology Chronic Health Evaluation II; CVVH, continuous veno-venous hemofiltration. P value represents live cohort vs. dead cohort. bHigh ratio means the ratio of CVVH therapy days with hypophosphatemia to total CVVH therapy days ≥0.58. cLow ratio means the ratio of CVVH therapy days with hypophosphatemia to total CVVH therapy days <0.58.